POC(Point of Care) 검사 시장 : 제품 유형, 검사 유형별, 검체 유형별, 기술별, 휴대성별, 구입 형태별, 용도별, 최종사용자별, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Point of Care Testing Market is projected to grow by USD 90.76 billion at a CAGR of 13.61% by 2032.

Point of care testing (POCT) is reshaping diagnostics by moving clinically actionable results closer to patients in hospitals, clinics, retail pharmacies, ambulances, workplaces, and homes. The category spans blood glucose monitoring, infectious disease testing, cardiac markers, coagulation, blood gas and electrolyte testing, pregnancy and fertility testing, urinalysis, and emerging molecular and multiplex diagnostic platforms.

Demand is supported by well-documented pressures on health systems, including aging populations, rising chronic disease prevalence, antimicrobial resistance, decentralized care models, and the need for faster clinical decisions. Regulatory oversight from agencies such as the U.S. Food and Drug Administration and frameworks such as Clinical Laboratory Improvement Amendments, the European Union In Vitro Diagnostic Regulation, and World Health Organization essential diagnostics guidance continue to shape quality, safety, access, and adoption.

Transformative Shifts in the POCT Landscape

The POCT landscape is shifting from single-analyte, operator-dependent devices toward connected, quality-controlled, and data-integrated diagnostic ecosystems. Laboratories and care networks increasingly evaluate point of care devices not only for speed, but also for analytical performance, interoperability, cybersecurity, operator training, traceability, and total cost of ownership.

COVID-19 accelerated public familiarity with rapid testing and demonstrated the operational value of decentralized diagnostics for triage, surveillance, and continuity of care. At the same time, reimbursement scrutiny, supply-chain resilience, and stricter in vitro diagnostic regulations are pushing manufacturers to validate performance across diverse populations and real-world settings. The competitive focus is moving toward platforms that combine usability, connectivity, quality assurance, and clinically meaningful turnaround time.

Cumulative Impact of Artificial Intelligence in POCT

Artificial intelligence is increasingly influencing point of care testing through automated image interpretation, signal analysis, decision support, quality monitoring, and workflow optimization. AI-enabled readers can help reduce subjectivity in lateral flow test interpretation, improve pattern recognition in digital microscopy, and flag anomalous results, device drift, or operator errors when paired with connected device data.

The cumulative impact is not only faster interpretation but also more consistent performance at distributed testing sites. However, AI adoption in POCT depends on transparent validation, bias assessment, clinical governance, cybersecurity, human oversight, and compliance with evolving medical device software regulations. Industry leaders must treat AI as a regulated clinical capability rather than a marketing layer.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

North America remains a mature point of care testing environment, supported by high healthcare spending, CLIA-waived testing pathways in the United States, chronic disease management programs, emergency care demand, and wide access through urgent care and retail health settings. Europe is shaped by decentralized care priorities, aging populations, antimicrobial stewardship, and the EU IVDR, which raises evidence expectations for diagnostic manufacturers and strengthens the role of post-market surveillance. Asia-Pacific is expanding through hospital modernization, infectious disease surveillance, diabetes management, aging-related care, and broader primary care access across China, India, Japan, Australia, South Korea, and ASEAN economies.

Latin America shows rising demand for rapid infectious disease, pregnancy, and chronic disease testing, although reimbursement variability, infrastructure gaps, and uneven laboratory access affect adoption. Middle East markets benefit from hospital investment, national health transformation programs, digital health initiatives, and demand for rapid emergency diagnostics. Africa relies heavily on POCT for HIV, malaria, tuberculosis, maternal health, antimicrobial stewardship, and outbreak response, with adoption tied to affordability, supply continuity, training, power reliability, and connectivity in low-resource settings.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

Across G7 countries, point of care testing adoption is closely linked to value-based care, emergency department efficiency, chronic disease monitoring, antimicrobial stewardship, and regulatory emphasis on evidence and quality systems. The European Union is strongly influenced by IVDR implementation, procurement standards, laboratory governance, and cross-border healthcare priorities, increasing the importance of clinical evidence, post-market surveillance, and interoperable reporting.

BRICS economies are important demand centers because of large patient populations, public health screening needs, infectious disease burdens, and expanding domestic diagnostic manufacturing. ASEAN countries are prioritizing primary care access, maternal and child health, noncommunicable disease management, and infectious disease readiness, while GCC markets are investing in high-acuity hospital infrastructure, emergency medicine, and digital health transformation. NATO members also emphasize deployable diagnostics for military medicine, emergency preparedness, field triage, and resilient health security systems.

Key Country Insights Across Major POCT Markets

The United States leads through broad clinical use of CLIA-waived tests, retail health expansion, decentralized testing models, and FDA-regulated diagnostic innovation, while Canada emphasizes access across large geographies, remote care delivery, and provincial health system integration. Mexico and Brazil show sustained demand for affordable rapid tests in public and private care, especially for infectious diseases, pregnancy testing, and chronic disease monitoring. In Europe, the United Kingdom, Germany, France, Italy, and Spain prioritize hospital efficiency, primary care access, chronic disease management, antimicrobial stewardship, and compliance with stricter IVD rules, while Russia maintains demand for localized diagnostics and distributed healthcare access across broad territories.

In Asia-Pacific, China is expanding domestic diagnostic capacity, hospital-based testing, infectious disease surveillance, and chronic disease management; India relies on POCT to extend access across tiered healthcare settings, rural clinics, pharmacies, and public health programs; and Japan emphasizes quality, aging-related care, emergency diagnostics, and advanced testing technologies. Australia supports POCT in remote and Aboriginal health services, emergency care, and chronic disease programs, while South Korea combines strong diagnostics manufacturing, hospital digitalization, and connected healthcare adoption.

Actionable Recommendations for POCT Industry Leaders

Industry leaders should prioritize clinically validated point of care testing platforms that demonstrate accuracy, usability, connectivity, traceability, and measurable workflow impact. Product strategies should align with real care pathways such as emergency triage, antimicrobial stewardship, diabetes management, cardiovascular risk assessment, respiratory infection testing, maternal health, and remote patient monitoring.

Manufacturers should invest in interoperability with electronic health records, operator lockout and quality control features, cybersecurity, data governance, and cloud-based fleet management. Commercial teams need region-specific evidence packages that address reimbursement, procurement, regulatory requirements, training capacity, and public health priorities. Partnerships with laboratories, pharmacies, primary care networks, hospitals, public health agencies, and telehealth providers can accelerate adoption while maintaining governance, quality, and clinical accountability.

Research Methodology

This executive summary is based on secondary research and analytical synthesis from publicly available, authoritative sources, including health agency guidance, regulatory frameworks, peer-reviewed literature, clinical practice trends, international health system priorities, and public health programs. Key reference points include FDA oversight of in vitro diagnostics and medical device software, CLIA requirements, EU IVDR implementation, WHO diagnostics guidance, and global initiatives addressing infectious diseases, chronic disease management, and decentralized care.

Insights were evaluated through a market-structure lens covering clinical need, technology readiness, regulatory requirements, procurement behavior, geographic access, health system infrastructure, quality assurance, and competitive differentiation. No unverified market-size figures, market share claims, or unsupported growth forecasts are used.

Conclusion

Point of care testing is becoming a core component of modern diagnostics because it reduces time to clinical action, supports decentralized care, improves triage, and strengthens disease surveillance. Its value is highest when speed is matched by analytical reliability, connected data capture, quality controls, operator training, and clear clinical protocols.

The next phase of POCT competition will favor organizations that integrate validated assays, AI-enabled interpretation, secure connectivity, interoperable reporting, and region-specific commercialization strategies. Stakeholders that balance innovation with regulatory rigor, affordability, and real-world usability will be best positioned to serve hospitals, community care, public health, emergency medicine, and home-based testing environments.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Point of Care Testing Market, by Product

• 7.1. Consumables Services & Software
  • 7.1.1. Consumables & Accessories
  • 7.1.2. Service Maintenance & Calibration
  • 7.1.3. Software & Connectivity
• 7.2. Instruments & Analyzers
  • 7.2.1. Benchtop Analyzers
  • 7.2.2. Molecular Platforms
  • 7.2.3. Portable Analyzers
  • 7.2.4. Readers & Scanners
• 7.3. Reagents & Assays
  • 7.3.1. Glucose Test Strips
  • 7.3.2. Hematology Reagents
  • 7.3.3. Immunoassay Reagents
  • 7.3.4. Lateral Flow Assay Reagents
  • 7.3.5. Molecular Assay Kits

8. Point of Care Testing Market, by Test Type

• 8.1. Blood Gases
• 8.2. Cardiac Markers
  • 8.2.1. B-type Natriuretic Peptide
  • 8.2.2. Troponin
• 8.3. Comprehensive Metabolic Panel
• 8.4. Drug Of Abuse Testing
• 8.5. Hematology
  • 8.5.1. Coagulation Tests
    • 8.5.1.1. Activated Partial Thromboplastin Time
    • 8.5.1.2. Fibrinogen Level
    • 8.5.1.3. Prothrombin Time & International Normalized Ratio
  • 8.5.2. Complete Blood Count
• 8.6. Infectious Disease
  • 8.6.1. Gastrointestinal Infection Tests
  • 8.6.2. Respiratory Infection Tests
  • 8.6.3. Sexually Transmitted Infection Tests
• 8.7. Molecular Diagnostics
• 8.8. Pregnancy & Fertility
• 8.9. Urinalysis

9. Point of Care Testing Market, by Sample Type

• 9.1. Blood
• 9.2. Nasal & Swab Samples
• 9.3. Saliva
• 9.4. Urine

10. Point of Care Testing Market, by Technology

• 10.1. Biosensor Electrochemical
• 10.2. Colorimetric Platforms
• 10.3. Immunoassay
• 10.4. Lateral Flow Assays
  • 10.4.1. Antibody Tests
  • 10.4.2. Antigen Tests
  • 10.4.3. Multiplex Lateral Flow
• 10.5. Microfluidics
• 10.6. PCR And Molecular

11. Point of Care Testing Market, by Portability

• 11.1. Benchtop Fixed Analyzers
• 11.2. Portable Handheld Devices

12. Point of Care Testing Market, by Mode of Purchase

• 12.1. Over-The-Counter Tests
• 12.2. Prescription-Based Tests

13. Point of Care Testing Market, by Application

• 13.1. Chronic Disease Management
• 13.2. Emergency And Critical Care
• 13.3. Infectious Disease Diagnosis
• 13.4. Occupational And Workplace Testing
• 13.5. Oncology Monitoring
• 13.6. Women Health

14. Point of Care Testing Market, by End User

• 14.1. Ambulatory Care Centers
• 14.2. Diagnostic Laboratories
• 14.3. Free-Standing Emergency Departments
• 14.4. Home Care
• 14.5. Hospitals & Clinics
• 14.6. Urgent Care Centers

15. Point of Care Testing Market, by Distribution Channel

• 15.1. Offline
  • 15.1.1. Direct Sales
  • 15.1.2. Distributor & Wholesale
  • 15.1.3. Retail & Pharmacy
• 15.2. Online

16. Point of Care Testing Market, by Region

• 16.1. Asia-Pacific
• 16.2. North America
• 16.3. Latin America
• 16.4. Europe
• 16.5. Middle East
• 16.6. Africa

17. Point of Care Testing Market, by Group

• 17.1. ASEAN
• 17.2. GCC
• 17.3. European Union
• 17.4. BRICS
• 17.5. G7
• 17.6. NATO

18. Point of Care Testing Market, by Country

• 18.1. United States
• 18.2. Canada
• 18.3. Mexico
• 18.4. Brazil
• 18.5. United Kingdom
• 18.6. Germany
• 18.7. France
• 18.8. Russia
• 18.9. Italy
• 18.10. Spain
• 18.11. China
• 18.12. India
• 18.13. Japan
• 18.14. Australia
• 18.15. South Korea

19. Competitive Landscape

• 19.1. Market Concentration Analysis, 2025
  • 19.1.1. Concentration Ratio (CR)
  • 19.1.2. Herfindahl Hirschman Index (HHI)
• 19.2. Recent Developments & Impact Analysis, 2025
• 19.3. Product Portfolio Analysis, 2025
• 19.4. Benchmarking Analysis, 2025

20. Company Profiles

• 20.1. Abaxis, Inc. by Zoetis Inc
• 20.2. Abbott Laboratories
• 20.3. AccuBioTech Co., Ltd.
• 20.4. ACON Laboratories, Inc.
• 20.5. Beckman Coulter
• 20.6. Becton, Dickinson and Company
• 20.7. Bio-Rad Laboratories, Inc.
• 20.8. bioMerieux SA
• 20.9. CardioGenics Holdings Inc.
• 20.10. Chembio Diagnostic Systems, Inc. by Biosynex
• 20.11. Danaher Corporation
• 20.12. EKF Diagnostics Holdings
• 20.13. F. Hoffmann-La Roche Ltd
• 20.14. GE Healthcare Technologies, Inc.
• 20.15. Medtronic Plc
• 20.16. Nova Biomedical Corporation
• 20.17. OraSure Technologies, Inc.
• 20.18. Quidel Corporation
• 20.19. Radiometer Medical ApS
• 20.20. Randox Laboratories Ltd.
• 20.21. Siemens Healthineers AG
• 20.22. Thermo Fisher Scientific Inc.